MX2015017505A - Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos. - Google Patents

Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos.

Info

Publication number
MX2015017505A
MX2015017505A MX2015017505A MX2015017505A MX2015017505A MX 2015017505 A MX2015017505 A MX 2015017505A MX 2015017505 A MX2015017505 A MX 2015017505A MX 2015017505 A MX2015017505 A MX 2015017505A MX 2015017505 A MX2015017505 A MX 2015017505A
Authority
MX
Mexico
Prior art keywords
stimuli
long
sensitive nanocarrier
term circulating
nanocarrier systems
Prior art date
Application number
MX2015017505A
Other languages
English (en)
Inventor
Eibl Hansjörg
Original Assignee
THERMOSOME GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THERMOSOME GmbH filed Critical THERMOSOME GmbH
Publication of MX2015017505A publication Critical patent/MX2015017505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)

Abstract

La invención se refiere a lípidos estereoespecíficos para terapia locoregional con sistemas de nanoportador sensibles a estímulos circulantes a largo plazo. Una modalidad preferida de los mismos es un liposoma termosensible para tratar tumores, en especial tumores de la vejiga urinaria y otros tumores localizados.
MX2015017505A 2013-06-18 2014-06-18 Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos. MX2015017505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13172469 2013-06-18
PCT/EP2014/062849 WO2014202680A1 (de) 2013-06-18 2014-06-18 Stereospezifische lipide zur lokoregionären therapie mit langzeitzirkulierenden stimuli-sensitiven nanocarriersystemen

Publications (1)

Publication Number Publication Date
MX2015017505A true MX2015017505A (es) 2016-08-05

Family

ID=48628349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017505A MX2015017505A (es) 2013-06-18 2014-06-18 Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos.

Country Status (18)

Country Link
US (1) US10251838B2 (es)
EP (1) EP3010488B1 (es)
JP (1) JP6501765B2 (es)
KR (1) KR102242183B1 (es)
CN (1) CN105431139B (es)
AU (1) AU2014283264C1 (es)
BR (1) BR112015031495B1 (es)
CA (1) CA2922627C (es)
DK (1) DK3010488T3 (es)
EA (1) EA033891B1 (es)
ES (1) ES2881699T3 (es)
HK (1) HK1217647A1 (es)
HU (1) HUE054713T2 (es)
IL (1) IL243212B (es)
MX (1) MX2015017505A (es)
PL (1) PL3010488T3 (es)
PT (1) PT3010488T (es)
WO (1) WO2014202680A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510859A (ja) * 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
CA3185118A1 (en) 2020-07-07 2022-01-13 Martin HOSSANN Liposome formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI874742A (fi) * 1987-10-28 1989-04-29 K & V Licencing Oy Foerfarande foer framstaellning av liposomer.
CA2246568C (en) * 1996-02-16 2007-08-07 Hans-Jorg Eibl Phosphatidyl oligoglycerols
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
DE10107165A1 (de) * 2001-02-15 2002-08-29 Max Planck Gesellschaft Thermolabiles Liposom mit geregelter Freigabetemperatur
DE10242367A1 (de) 2002-09-12 2004-03-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Thermolabiles Liposom mit geregelter Freigabetemperatur
WO2009073517A2 (en) * 2007-11-30 2009-06-11 Indevus Pharmaceuticals, Inc. Intravesical compositions with valrubicin for the treatment of bladder cancer
JP5382567B2 (ja) 2008-05-02 2014-01-08 公立大学法人大阪府立大学 温度感受性リポソーム
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood

Also Published As

Publication number Publication date
EA201690029A1 (ru) 2016-05-31
AU2014283264A1 (en) 2016-02-04
EA033891B1 (ru) 2019-12-05
AU2014283264C1 (en) 2019-08-29
JP6501765B2 (ja) 2019-04-17
EP3010488A1 (de) 2016-04-27
CN105431139A (zh) 2016-03-23
PT3010488T (pt) 2021-08-03
HUE054713T2 (hu) 2021-09-28
AU2014283264B2 (en) 2019-05-02
US10251838B2 (en) 2019-04-09
BR112015031495A2 (pt) 2017-07-25
PL3010488T3 (pl) 2021-11-15
CN105431139B (zh) 2019-10-01
US20160136092A1 (en) 2016-05-19
WO2014202680A1 (de) 2014-12-24
ES2881699T3 (es) 2021-11-30
KR102242183B1 (ko) 2021-04-20
IL243212A0 (en) 2016-02-29
IL243212B (en) 2020-01-30
JP2016523242A (ja) 2016-08-08
DK3010488T3 (da) 2021-05-31
BR112015031495B1 (pt) 2023-04-11
KR20160026984A (ko) 2016-03-09
HK1217647A1 (zh) 2017-01-20
CA2922627C (en) 2022-03-08
CA2922627A1 (en) 2014-12-24
EP3010488B1 (de) 2021-05-05

Similar Documents

Publication Publication Date Title
HK1261924A1 (zh) 用於實施治療，如癌症治療的控制器和柔性線圈
HK1244847A1 (zh) 用於膀胱癌症的治療，診斷和預後方法
IL254294A0 (en) Topical local neuro-effective treatment with cannabinoids
EP3307371A4 (en) CATHETER WITH PRE-FORMULATED GEOMETRY FOR BODY LUMEN ACCESS
EP3076977A4 (en) Combination therapy for treating cancer
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
DK3027208T3 (da) Cancerdiagnose og -terapi, der involverer cancerstamceller
EP2937080A4 (en) ANTICANCER NANOPARTICLES WITH AMPLIFIED TARGET SPECIFICITY AND PREPARATION METHOD THEREOF
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
EP3052122A4 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
EP3007756A4 (en) Catheter-assisted tumor treatment
MX2015014344A (es) Terapia contra el cancer.
CL2016000770A1 (es) Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
EP3266865A4 (en) Cell therapeutic agent for cancer treatment and combination therapy with same
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.
BR112018012116A2 (pt) terapia intravesical para câncer de bexiga
MX2015017505A (es) Lípidos estereoespecíficos para terapia locorregional con sistemas nanotransportadores que circulan a largo plazo sensibles a estímulos.
EP3047834A4 (en) Drug supply body, and drug supply unit
EP3158886B8 (de) Einlage mit einem einlagengrundkörper und einem einlagenkern
HK1213475A1 (zh) 用於癌症治療的 、卡培他濱和奧沙利鉑的組合
GB201308363D0 (en) Tumour therapy
MX2018001658A (es) Agente terapeutico contra tumores.
KR20150002727U (ko) 온냉열 붕대

Legal Events

Date Code Title Description
FG Grant or registration